PravastatinCAS# 81093-37-0 |
2D Structure
- Clopidogrel
Catalog No.:BCC2497
CAS No.:120202-66-6
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
Cas No. | 81093-37-0 | SDF | Download SDF |
PubChem ID | 54687 | Appearance | Powder |
Formula | C23H36O7 | M.Wt | 424.53 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | >14.1mg/mL in DMSO | ||
Chemical Name | (3R,5R)-7-[(1S,2S,6S,8S,8aR)-6-hydroxy-2-methyl-8-[(2S)-2-methylbutanoyl]oxy-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]-3,5-dihydroxyheptanoic acid | ||
SMILES | CCC(C)C(=O)OC1CC(C=C2C1C(C(C=C2)C)CCC(CC(CC(=O)O)O)O)O | ||
Standard InChIKey | TUZYXOIXSAXUGO-PZAWKZKUSA-N | ||
Standard InChI | InChI=1S/C23H36O7/c1-4-13(2)23(29)30-20-11-17(25)9-15-6-5-14(3)19(22(15)20)8-7-16(24)10-18(26)12-21(27)28/h5-6,9,13-14,16-20,22,24-26H,4,7-8,10-12H2,1-3H3,(H,27,28)/t13-,14-,16+,17+,18+,19-,20-,22-/m0/s1 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | Pravastatin is an HMG-CoA reductase inhibitor against sterol synthesis with IC50 of 5.6 μM.
Target: HMG-CoA reductase
Pravastatin (marketed as Pravachol or Selektine) is a member of the drug class of statins, used in combination with diet, exercise, and weight-loss for lowering cholesterol and preventing cardiovascular disease.
Pravastatin is primarily used for the treatment of dyslipidemia and the prevention of cardiovascular disease. It is recommended to be used only after other measures such as diet, exercise, and weight reduction have not improved cholesterol levels.The evidence for the use of pravastatin is generally weaker than for other statins. The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT), failed to demonstrate a difference in all-cause mortality or nonfatal myocardial infarction/fatal coronary heart disease rates between patients receiving pravastatin 40mg daily (a common starting dose) and those receiving usual care. References: |
Pravastatin Dilution Calculator
Pravastatin Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 2.3555 mL | 11.7777 mL | 23.5555 mL | 47.1109 mL | 58.8887 mL |
5 mM | 0.4711 mL | 2.3555 mL | 4.7111 mL | 9.4222 mL | 11.7777 mL |
10 mM | 0.2356 mL | 1.1778 mL | 2.3555 mL | 4.7111 mL | 5.8889 mL |
50 mM | 0.0471 mL | 0.2356 mL | 0.4711 mL | 0.9422 mL | 1.1778 mL |
100 mM | 0.0236 mL | 0.1178 mL | 0.2356 mL | 0.4711 mL | 0.5889 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Pravastatin is an HMG-CoA reductase inhibitor against sterol synthesis with IC50 of 5.6 μM.
- Kauniolide
Catalog No.:BCC5313
CAS No.:81066-45-7
- EUK 134
Catalog No.:BCC4317
CAS No.:81065-76-1
- Methyl 4-prenyloxycinnamate
Catalog No.:BCN7520
CAS No.:81053-49-8
- 4-Hydroxy-4-(methoxycarbonylmethyl)cyclohexanone
Catalog No.:BCN1346
CAS No.:81053-14-7
- Rhodamine B
Catalog No.:BCN7215
CAS No.:81-88-9
- Warfarin
Catalog No.:BCC5221
CAS No.:81-81-2
- Purpurin
Catalog No.:BCN3477
CAS No.:81-54-9
- Sennoside A
Catalog No.:BCN1002
CAS No.:81-27-6
- Cholic acid
Catalog No.:BCN1286
CAS No.:81-25-4
- Taurocholic acid
Catalog No.:BCN6954
CAS No.:81-24-3
- 2-Amino-1-naphthalenesulfonic acid
Catalog No.:BCC8519
CAS No.:81-16-3
- Musk ketone
Catalog No.:BCN8357
CAS No.:81-14-1
- Cisapride
Catalog No.:BCC4207
CAS No.:81098-60-4
- Clarithromycin
Catalog No.:BCC9219
CAS No.:81103-11-9
- Racecadotril
Catalog No.:BCC4614
CAS No.:81110-73-8
- N-Nonyldeoxynojirimycin
Catalog No.:BCC7752
CAS No.:81117-35-3
- (Z)-Lachnophyllum lactone
Catalog No.:BCN4746
CAS No.:81122-95-4
- Cilastatin sodium
Catalog No.:BCC7457
CAS No.:81129-83-1
- Pravastatin sodium
Catalog No.:BCC2321
CAS No.:81131-70-6
- RR-src
Catalog No.:BCC6956
CAS No.:81156-93-6
- Imiloxan hydrochloride
Catalog No.:BCC6875
CAS No.:81167-22-8
- Apatinib
Catalog No.:BCC5099
CAS No.:811803-05-1
- Boc-D-Tyr(2-Br-Z)-OH
Catalog No.:BCC3464
CAS No.:81189-61-9
- Panaxynol
Catalog No.:BCN3833
CAS No.:81203-57-8
Effects of pitavastatin and pravastatin on markers of immune activation and arterial inflammation in HIV.[Pubmed:28252528]
AIDS. 2017 Mar 27;31(6):797-806.
OBJECTIVE: Persistent immune activation is thought to contribute to increased cardiovascular disease risk in HIV and statins may help modulate systemic immune activation. We aimed to compare the effects of two key statins on markers of systemic immune activation and arterial inflammation in the HIV population. DESIGN: Double-blind, active-controlled, parallel-group comparative trial performed in 45 sites. METHODS: Two hundred and fifty-two antiretroviral therapy-treated HIV-infected participants with dyslipidemia were randomized (1 : 1) to pitavastatin 4 mg daily vs. Pravastatin 40 mg daily in the HIV-infected patieNts and TREatment with PItavastatin vs. Pravastatin for Dyslipidemia (INTREPID) trial. In this analysis of the INTREPID trial, we assessed markers of immune activation and arterial inflammation using a modified intent-to-treat population. This trial is registered with ClinicalTrials.gov (NCT01301066). RESULTS: One hundred and twenty-six participants were randomized to receive pitavastatin and 126 to Pravastatin. Ninety-nine participants in the pitavastatin group and 91 participants in the Pravastatin group completed the study. Median age was 50 (45, 56) years [median (interquartile range)]. Baseline, low-density lipoprotein-cholestrol (LDL-C) was 153 (135, 171) mg/dl, log HIV-1 viral load was 1.1 +/- 0.2 copies/ml, and CD4 cell count was 580 (439, 794) cells/mul. At week 52, the pitavastatin group had a significantly greater reduction (% change) compared with Pravastatin in soluble CD14 (sCD14), (-10.0 vs. 0.6%, P = 0.02), oxidized LDL (oxLDL) (-26.9 vs. -17.5%, P = 0.02), and lipoprotein-associated phospholipase 2 (Lp-PLA2) (-26.6 vs. -15.5%, P = 0.005) (pitavastatin vs. Pravastatin). CONCLUSION: Fifty-two weeks of pitavastatin 4 mg daily (vs. Pravastatin 40 mg daily) led to a greater reduction in select markers of immune activation and arterial inflammation (sCD14, oxLDL, and LpPLA2) among HIV-infected participants. Further work is needed to assess whether immune-modulatory effects of pitavastatin reduce cardiovascular disease risk in HIV.
Multicenter, Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Pravastatin Added to First-Line Standard Chemotherapy in Small-Cell Lung Cancer (LUNGSTAR).[Pubmed:28240967]
J Clin Oncol. 2017 May 10;35(14):1506-1514.
Purpose Treating small-cell lung cancer (SCLC) remains a therapeutic challenge. Experimental studies show that statins exert additive effects with agents, such as cisplatin, to impair tumor growth, and observational studies suggest that statins combined with anticancer therapies delay relapse and prolong life in several cancer types. To our knowledge, we report the first large, randomized, placebo-controlled, double-blind trial of a statin with standard-of-care for patients with cancer, specifically SCLC. Patients and Methods Patients with confirmed SCLC (limited or extensive disease) and performance status 0 to 3 were randomly assigned to receive daily Pravastatin 40 mg or placebo, combined with up to six cycles of etoposide plus cisplatin or carboplatin every 3 weeks, until disease progression or intolerable toxicity. Primary end point was overall survival (OS), and secondary end points were progression-free survival (PFS), response rate, and toxicity. Results Eight hundred forty-six patients from 91 United Kingdom hospitals were recruited. The median age of recruited patients was 64 years of age, 43% had limited disease, and 57% had extensive disease. There were 758 deaths and 787 PFS events. No benefit was found for Pravastatin, either in all patients or in several subgroups. For Pravastatin versus placebo, the 2-year OS rate was 13.2% (95% CI, 10.0 to 16.7) versus 14.1% (95% CI, 10.9 to 17.7), respectively, with a hazard ratio of 1.01 (95% CI, 0.88 to 1.16; P = .90. The median OS was 10.7 months v 10.6 months, respectively. The median PFS was 7.7 months v 7.3 months, respectively. The median OS (Pravastatin v placebo) was 14.6 months in both groups for limited disease and 9.1 months versus 8.8 months, respectively, for extensive disease. Adverse events were similar between groups. Conclusion Pravastatin 40 mg combined with standard SCLC therapy, although safe, does not benefit patients. Our conclusions are the same as those found in all four much smaller, randomized, placebo-controlled trials specifically designed to evaluate statin therapy in patients with cancer.
Design of fixed dose combination and physicochemical characterization of enteric-coated bilayer tablet with circadian rhythmic variations containing telmisartan and pravastatin sodium.[Pubmed:28330645]
Int J Pharm. 2017 May 15;523(1):343-356.
The aim of this study was to investigate a fixed dose combination (FDC) of telmisartan (TEL) and Pravastatin sodium (PRA) in enteric-coated bilayer tablets, which was designed for once-daily bedtime dose in order to match circadian rhythmic variations of hypertension and cholesterol synthesis and optimize the patient friendly dosing treatment. Due to the poor aqueous solubility of TEL, ternary solid dispersions (SD) consisting of TEL, polyethylene glycol 6000 (PEG 6000) and magnesium oxide (MgO) were designed to enhance its dissolution rate in intestinal fluid. MgO was added as an effective alkalizer to maintain the high microenvironmental pH of the saturated solution in the immediate vicinity of TEL particles because TEL is known to be ionizable but poorly soluble in intestinal fluid. In contrast, PRA is known to be very unstable in low pH conditions. In the SD system, TEL was present in an amorphous structure and formed an intermolecular hydrogen bonding with MgO, giving complete drug release without precipitation in intestinal fluid. In addition, the amount of hydrophilic carrier (PEG 6000) was also a factor. In the design of tablet formulation, the diluents and superdisintegrants could play a key role in release profiles. Then, to fulfill the unmet needs of the two model drugs and match circadian rhythmic variations of hypertension and cholesterol synthesis, enteric-coated bilayer tablet consisting of TEL SD and PRA was finally prepared using Acryl-EZE((R)) as an enteric coating material. Prior to enteric coating, a seal coating layer (Opadry((R)), 2% weight gains) was firstly introduced to separate the core bilayer tablet from the acidic enteric coating polymers to avoid premature degradation. Dissolution profiles of finished tablets revealed that enteric-coated bilayer tablets with 6% weight gains remained intact in acidic media (pH 1.0) for 2h and then released drugs completely within 45min after switching to the intestinal media (pH 6.8). It was observed that enteric-coated bilayer tablets were stable during 3 month under the accelerated condition of 40 degrees C/75% RH. The delayed drug release and bedtime dosage regimen using enteric-coated bilayer tablet containing TEL and PRA, matching the circadian rhythms of hypertension and hyperlipidemia can provide therapeutic benefits for elderly patients in terms of maximizing the therapeutic effects.